Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coherent, Zeiss Supplying Lasers Free For Visudyne Treatment IND Study

This article was originally published in The Gray Sheet

Executive Summary

Laser manufacturers Coherent and Zeiss are providing their device at no charge to physicians participating in Ciba Vision's treatment IND program for the photodynamic age-related macular degeneration treatment Visudyne (verteprofin).

You may also be interested in...

Coherent, Zeiss Eye PDT Market Opportunity Pending Visudyne NDA Approval

Coherent, Inc. and Zeiss Humphrey Systems are preparing to compete head-to-head for the placement of photodynamic therapy (PDT) lasers to perform "wet" age-related macular degeneration (AMD) therapy in conjunction with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) pending imminent FDA approval for the combined drug/device treatment.

Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch

As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts